Header Logo

Connection

Kamban Hirasen to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Kamban Hirasen has written about Cost-Benefit Analysis.
Kamban Hirasen
Connection Strength
0,210
Cost-Benefit Analysis
  1. Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
    View in: PubMed
    Score: 0,210
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.